## CERTIFICATE OF ANALYSIS

## Purified AAV2-CMV-Luciferase (Lot 17-480)

(for research use only)

## Storage Conditions

The AAV vectors should be stored at $-80^{\circ} \mathrm{C}$ for long term usage. When storing for frequent use, $4^{\circ} \mathrm{C}$ is recommended. Avoid storing at $-20^{\circ} \mathrm{C}$.

## Instruction

Due to the nature of AAV2 is prompt to aggregate, please vortex and sonicate the AAV2 viruses prior to usage.

## Shelf Life

3 years when stored at $-80^{\circ} \mathrm{C}$. (AAV)

## Shipping Conditions

Ice packs Overnight

## Description

AAV2-CMV-Luciferase was produced in insect Sf9 cells by infection with rBV-inCap2-inRepCap-kozak (V104) (Fig 2) and rBV-CMV-Luciferase (AVA13) (Fig 3).

The vectors were purified through 2 rounds of CsCl ultracentrifugations. The CsCl was removed through buffer exchange with 2 PD-10 desalting columns. The final AAVs are in $1 x$ PBS +100 mM sodium citrate $+0.001 \%$ pluronic F-68 buffer.

The vectors are for research use only, not for any human use.
QPCR Titer
Lot 17-480: $2 \mathrm{E}+13 \mathrm{vg} / \mathrm{mL}$ (final diluted)

The vectors were sterilized with $0.22 \mu \mathrm{~m}$ filter. SDS-PAGE and InstantBlue Staining (Expedeon) verified the purity of the vectors (Fig. 1). Real-time PCR determined the titers of the AAV samples.


Fig. 1. SDS-PAGE and InstantBlue Staining of purified AAV2-CMV-Luciferase (Lot: 17-480).

## Plasmids map



Fig. 2. Diagram of plasmid used to generate rBV- inCap2-inRepCap-kozak-hr2 (V104).


Fig. 3. Diagram of plasmid used to generate rBV- CMV-Luciferase (AVA13).
Approved by: M~TM Monday, September 13, 2021

